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Sacrospinous hysteropexy versus vaginal hysterectomy with 
uterosacral ligament suspension in women with uterine  prolapse 
stage 2 or higher: observational follow-up of a multicentre 
 randomised trial
Sascha F M Schulten,1,2 Renée J Detollenaere,1 Jelle Stekelenburg,3,4 Joanna IntHout,2  
Kirsten B Kluivers,5 Hugo W F van Eijndhoven1
ABSTRACT
OBJECTIVE
To evaluate the effectiveness and success of uterus 
preserving sacrospinous hysteropexy as an alternative 
to vaginal hysterectomy with uterosacral ligament 
suspension in the surgical treatment of uterine 
prolapse five years after surgery.
DESIGN
Observational follow-up of SAVE U (sacrospinous 
fixation versus vaginal hysterectomy in treatment of 
uterine prolapse ≥2) randomised controlled trial.
SETTING
Four non-university teaching hospitals, the 
Netherlands.
PARTICIPANTS
204 of 208 healthy women in the initial trial (2009-
12) with uterine prolapse stage 2 or higher requiring 
surgery and no history of pelvic floor surgery who 
had been randomised to sacrospinous hysteropexy 
or vaginal hysterectomy with uterosacral ligament 
suspension. The women were followed annually for 
five years after surgery. This extended trial reports the 
results at five years.
MAIN OUTCOME MEASURES
Prespecified primary outcome evaluated at five year 
follow-up was recurrent prolapse of the uterus or 
vaginal vault (apical compartment) stage 2 or higher 
evaluated by pelvic organ prolapse quantification 
system in combination with bothersome bulge 
symptoms or repeat surgery for recurrent apical 
prolapse. Secondary outcomes were overall 
anatomical failure (recurrent prolapse stage 2 or 
higher in apical, anterior, or posterior compartment), 
composite outcome of success (defined as no 
prolapse beyond the hymen, no bothersome bulge 
symptoms, and no repeat surgery or pessary use for 
recurrent prolapse), functional outcome, quality of 
life, repeat surgery, and sexual functioning.
RESULTS
At five years, surgical failure of the apical 
compartment with bothersome bulge symptoms or 
repeat surgery occurred in one woman (1%) after 
sacrospinous hysteropexy compared with eight 
women (7.8%) after vaginal hysterectomy with 
uterosacral ligament suspension (difference−6.7%, 
95% confidence interval −12.8% to−0.7%). A 
statistically significant difference was found in 
composite outcome of success between sacrospinous 
hysteropexy and vaginal hysterectomy (89/102 (87%) 
v 77/102 (76%). The other secondary outcomes did 
not differ. Time-to-event analysis at five years showed 
no differences between the interventions.
CONCLUSIONS
At five year follow-up significantly less anatomical 
recurrences of the apical compartment with 
bothersome bulge symptoms or repeat surgery were 
found after sacrospinous hysteropexy compared 
with vaginal hysterectomy with uterosacral ligament 
suspension. After hysteropexy a higher proportion of 
women had a composite outcome of success. Time-
to-event analysis showed no differences in outcomes 
between the procedures.
TRIAL REGISTRATION
trialregister.nl NTR1866.
Introduction
Uterine prolapse is a common health problem, with 
increasing incidence due to aging populations and 
rising obesity rates.1 2 Women’s lifetime risk for 
prolapse surgery is 11-20%, and worldwide vaginal 
hysterectomy is the most common surgical procedure 
for uterine prolapse.3 4 Studies comparing vaginal 
hysterectomy with uterus preserving procedures 
are limited, and no data are available on long term 
follow-up. Guidelines for pelvic organ prolapse 
are therefore ambiguous, resulting in variation in 
treatment.5 The SAVE U (sacrospinous fixation versus 
vaginal hysterectomy in treatment of uterine prolapse 
≥2) randomised trial compared uterus preservation 
with hysterectomy on a large scale with relevant 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Vaginal hysterectomy is the standard treatment for uterine prolapse, but uterus 
preservation is gaining popularity
Sacrospinous hysteropexy was non-inferior to vaginal hysterectomy with 
suspension of the uterosacral ligaments for recurrent prolapse of the apical 
compartment with bothersome bulge symptoms or repeat surgery after 12 
months’ follow-up
Overall anatomical outcome, quality of life, subjective outcome, hospital stay, 
recovery, complications, and sexual functioning did not differ
WHAT THIS STUDY ADDS
Follow-up at five years shows that uterine preservation is more effective than 
vaginal hysterectomy with uterosacral ligament suspension, and the risk for 
retreatment of recurrent prolapse or malignancy is low
Women who require surgical correction of uterine prolapse should be given the 
opportunity to choose uterus preservation and avoid hysterectomy
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outcome measures.6 Treatment with sacrospinous 
hysteropexy was non-inferior to vaginal hysterectomy 
with suspension of the uterosacral ligaments for 
surgical failure of the apical compartment after 12 
months’ follow-up. No notable differences were found 
between the interventions for overall anatomical 
and surgical failure, functional outcome, quality of 
life, complications, postoperative recovery, length 
of hospital stay, and sexual functioning. One of the 
study’s limitations was short duration of follow-up 
(12 months). Two recent systematic reviews with 
meta-analysis on apical pelvic organ prolapse surgery 
confirmed the short term results of the SAVE U trial.7 
8 The studies also concluded that long term follow-up 
of the comparison between vaginal hysterectomy with 
apical suspension and vaginal hysteropexy is necessary 
because the impact of the uterus on prolapse outcomes 
many years after surgery is still unknown. We report 
the five year outcomes in women after sacrospinous 
hysteropexy or vaginal hysterectomy with suspension 
of the uterosacral ligaments enrolled in the SAVE U 
randomised trial.
Methods
Study design
Details of the trial protocol have been published 
previously.6 9 All women gave written informed consent 
before randomisation.
In the original trial, women with uterine prolapse 
at stage 2 (uterine prolapse 1 cm above or beyond 
the hymen, according to the Pelvic Organ Prolapse 
Quantification (POP-Q) system) or higher were 
randomly assigned to sacrospinous hysteropexy or 
vaginal hysterectomy with suspension of the uterosacral 
ligaments in a non-blinded multicentre randomised 
controlled non-inferiority trial. Concomitant repair of 
anterior or posterior vaginal prolapse (colporrhaphy) 
was allowed, as was anti-incontinence surgery. 
We excluded women with previous pelvic floor or 
prolapse surgery, known malignancy, an abnormal 
cervical smear test result, a wish to preserve fertility, 
language barriers, immunological or haematological 
disorders interfering with recovery after surgery, 
abnormal ultrasound findings of the uterus or ovaries, 
and abnormal uterine bleeding. The women were 
randomly allocated in a 1:1 ratio using a web based 
application with computer generated randomisation 
tables in blocks of four, stratified by hospital and stage 
of uterine prolapse. The trial was non-blinded as it 
was impossible to blind surgeons and women to the 
allocated surgical procedure. An independent doctor 
or specialist nurse not involved in treatment carried 
out the follow-up visits.
Outcome measures
The primary outcome of the original SAVE U study was 
surgical failure of the apical compartment, defined as 
a recurrent prolapse stage 2 or higher of the uterus 
or vaginal vault (apical compartment) evaluated by 
the POP-Q system in combination with bothersome 
bulge symptoms or repeat surgery for recurrent apical 
prolapse after 12 months follow-up. This outcome was 
also used as the primary outcome after five years. The 
predefined secondary outcomes at five year follow-
up included overall anatomical failure (pelvic organ 
prolapse stage 2 or higher in any compartment), a 
composite outcome of success (defined as no prolapse 
beyond the hymen, no bothersome bulge symptoms, 
and no repeat surgery or pessary use for recurrent 
prolapse), functional outcome, quality of life, repeat 
surgery, and sexual functioning.
Interventions
The surgeons were provided with a detailed guideline 
of the study interventions to ensure a uniform 
technique.6 9
Sacrospinous hysteropexy—Vaginal sacrospinous 
hysteropexy was performed unilaterally to the right 
sacrospinous ligament. The posterior vaginal wall 
was incised and the sacrospinous ligament accessed 
through the pararectal space. Two permanent sutures 
(Prolene 1.0; Ethicon, Somerville, NJ) were placed 
under direct vision through the sacrospinous ligament 
at least 2 cm from the ischial spine. Additional anterior 
or posterior vaginal wall repair or incontinence surgery 
was performed as required. Both ends of the permanent 
sutures were placed through the posterior side of the 
cervix and tightened and the uterus redressed. The 
posterior vaginal wall was closed with absorbable 
sutures (Vicryl 2; Ethicon, Somerville, NJ). (For further 
details see www.youtube.com/watch?v=ySSfy2A1_RM 
and www.youtube.com/watch?v=wjct1r37sTw).
Vaginal hysterectomy—The vaginal wall around 
the cervix was circumcised. After bladder and bowel 
dissection the anterior and posterior peritoneum were 
opened. The uterosacral ligaments—strong supportive 
ligaments that attach the cervix to the sacrum— were 
identified, ligated, and transected. The uterus was 
released in several steps using clamps and sutures. 
After removal of the uterus, the surgical pedicles 
were inspected for haemostasis and the adnexa were 
inspected for abnormalities. The peritoneum was 
closed using a delayed absorbable suture (Vicryl 1.0; 
Ethicon, Somerville, NJ). Additional vault suspension 
in this study was performed by suspension of the 
uterosacral ligaments. This technique has been 
described previously and involves the attachment of 
the uterosacral ligaments to the vaginal vault with two 
delayed absorbable sutures (Vicryl 1.0, Ethicon).9 The 
sutures were placed as high as possible on the visible 
part of the ligament, which in general was caudal 
to the level of the ischial spine thereby restoring 
normal support to the apical compartment.10 Again, 
concomitant anterior or posterior vaginal wall repair or 
anti-incontinence surgery was performed if indicated.
Measurements and procedures
After the initial 12 month follow-up, women attended 
annual appointments at hospital for five years after 
surgery. Pelvic organ prolapse was staged during 
follow-up using the POP-Q system, and women 
completed validated health related and disease specific 
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quality of life questionnaires: short form-36, Euroqol 
5D, urogenital distress inventory, defecatory distress 
inventory, and incontinency impact questionnaire.11-14 
The presence of bothersome bulge symptoms after 
surgery was defined as a positive answer to any of 
the following questions from the urogenital distress 
inventory: “Do you experience a sensation of bulging 
or protrusion from the vagina?” and “Do you have a 
bulge or something fallen out that you can see in the 
vagina?” in combination with a response “somewhat 
bothered” to “ very much bothered” to the question 
“how much does this bother you?” To assess sexual 
functioning, we used the 12 item pelvic organ prolapse/
urinary incontinence sexual questionnaire, translated 
from the validated questionnaire but not validated for 
Dutch language at that time.15
Statistical analysis
The sample size for this trial was based on the primary 
outcome of the original trial at 12 months’ follow-up 
and reported previously.9 We assessed study outcomes 
by intention-to-treat analysis and surgical failure and 
composite outcome of success also by per protocol 
analysis. This analysis included women who completed 
the entire treatment protocol as originally planned, 
with availability of the POP-Q scores at five year follow-
up and absence of major deviations from the protocol. 
We evaluated the outcomes at five year follow-up by 
frequencies and proportions and used the Agresti-
Coull method to calculate 95% confidence intervals 
for differences in proportions.16 To account for missing 
data on anatomical outcome at five year follow-up, we 
applied two strategies. For the first strategy, we used 
the last observation carried forward with data from the 
last available follow-up visit. If data were not available, 
we excluded the woman from the intention-to-treat last 
observation carried forward analysis. Furthermore, we 
applied conservative imputation by imputing a failure 
for all women with missing data at five year follow-up 
(worst case scenario). If questionnaires were missing, 
we obtained information on the presence or absence 
of bothersome bulge symptoms from the case record 
form of the follow-up visit. For the second strategy, 
we performed time-to-event (survival) analysis using 
a Kaplan-Meier approach to estimate the cumulative 
incidence at five years of follow-up, and calculated the 
difference in cumulative incidences with corresponding 
95% confidence intervals.
Statistical significance was evaluated using Fisher’s 
exact tests and Mann-Whitney U tests to compare 
proportions and continuous variables between the 
groups. We used paired sample t tests to compare mean 
continuous data within groups. All statistical analyses 
were performed with SPSS for windows (version 
24.0.0.1).
Patient and public involvement
No patients were involved in the design and 
implementation of the study, the dissemination of 
results, setting the research question or the outcome 
measures, or recruitment.
Results
In the original trial, 208 women were randomly 
assigned to sacrospinous hysteropexy (n=103) or 
vaginal hysterectomy with uterosacral ligament 
suspension (n=105) between 27 November 2009 and 
12 March 2012. Figure 1 shows the flow of women 
through the study. A total of 204 women were eligible 
for the last observation carried forward analysis at 
five year follow-up. One woman developed severe 
complications during hospital stay after vaginal 
hysterectomy and died eight days after surgery. Three 
women withdrew consent before the first follow-up 
visit at six months. All four women were excluded from 
the last observation carried forward analysis.
Two women were lost to follow-up because they 
died. These deaths were from causes unrelated to the 
study and we applied last observation carried forward 
on their outcomes.
Two women received sacrospinous hysteropexy 
instead of vaginal hysterectomy owing to technical 
difficulties during surgery.6 According to the intention-
to-treat principle, we included these women in the 
intention-to-treat analysis, with all women analysed as 
randomised. For the per protocol analysis, we excluded 
women with major protocol deviations (n=9), women 
who were lost to follow-up (n=22,) and women with 
missing or incomplete POP-Q scores (n=18).
Baseline characteristics of women did not differ 
noticeably (table 1). Table 2 and figure 2 show the results 
for surgical and anatomical failure, success, and repeat 
surgery. Surgical failure of the apical compartment with 
bothersome bulge symptoms or repeat surgery occurred 
in only one of 102 women (1%) after sacrospinous 
hysteropexy compared with eight of 102 women (8%) 
after vaginal hysterectomy with uterosacral ligament 
suspension (difference −6.7%, 95% confidence interval 
−12.8% to −0.7%) for the last observation carried 
forward approach. In the intention-to-treat analysis 
with conservative imputation, surgical failure of the 
apical compartment with bothersome bulge symptoms 
or repeat surgery occurred in 16 of 103 women (16%) 
after sacrospinous hysteropexy and 27 of 105 women 
(26%) after vaginal hysterectomy (difference −9.8%, 95% 
confidence interval −20.9 to 1.2). The per protocol analysis 
showed surgical failure of the apical compartment in none 
of 88 women after sacrospinous hysteropexy and four of 
78 women (5%) after vaginal hysterectomy (difference 
−5.1%, 95% confidence interval −10.9% to 0.7%). In 
the time-to-event analysis surgical failure was found in 
four of 102 women (4%) after sacrospinous hysteropexy 
and nine of 102 women (9%) after vaginal hysterectomy 
(difference −4.7%, 95% confidence interval −11.4% to 
2.0%). Table 3 shows the characteristics of women with 
surgical failure of the apical compartment.
Overall anatomical failure occurred in 46 of 102 
women (45%) after sacrospinous hysteropexy and 
51 of 102 women (50%) after vaginal hysterectomy 
(difference −4.8%, 95% confidence interval −18.5% 
to 8.9%). No differences were found for anatomical 
failure in the different compartments except for the 
posterior compartment: five of 102 women (5%) had 
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prolapse stage 2 or higher of the posterior vaginal wall 
after sacrospinous hysteropexy and 18 of 101 women 
(18%) after vaginal hysterectomy (difference −12.7%, 
95% confidence interval −21.5% to −3.9%). Time-to-
event analysis showed overall anatomical failure in 73 
of 102 women (72%) after sacrospinous hysteropexy 
and 78 of 102 women (77%) after vaginal hysterectomy 
(difference −5.0%, −17.1% to 7.1%).
In the last observation carried forward approach, 
treatment success was significant in 89 of 102 
women (87%) in the sacrospinous hysteropexy group 
compared with 77 of 102 women (76%) in the vaginal 
Assessed for eligibility
Excluded
Did not meet inclusion criteria
Declined to participate
Other
11
155
15
Allocated to vaginal hysterectomy
Received vaginal hysterectomy
Received sacrospinous hysteropexy
  instead of vaginal hysterectomy owing to
  technical difficulties during surgery
Underwent abdominal hysterectomy owing
  to adhesions identified by laparoscopy 
102
2
1
Allocated to sacrospinous hysteropexy
Received sacrospinous hysteropexy
Received sacrospinous hysteropexy
  instead of vaginal hysterectomy owing to
  technical difficulties during surgery
105
2
Randomised
389
208
103 105
181
Discontinued follow-up at 1 year
  Lost to follow-up
  Died
Missing POP-Q scores
3
4
2
1
Discontinued follow-up at 1 year
  Lost to follow-up
  Laparoscopic hysterectomy
    owing to endometrial cancer
5
4
1
Discontinued follow-up at 5 years
  Lost to follow-up
  Died
Missing POP-Q scores
13
11
11
2
Discontinued follow-up at 5 years
  Lost to follow-up
  Died
Missing POP-Q scores
9
7
8
1
Analysed for primary outcome intention to
  treat with last observation carried
  forward at 1 year
Analysed for primary outcome intention to
  treat with conservative imputation
Analysed for primary outcome per protocol
102
103
98
Analysed for primary outcome intention to
  treat with last observation carried
  forward at 1 year
Analysed for primary outcome intention to
  treat with conservative imputation
Analysed for primary outcome per protocol
100
105
90
Analysed for primary outcome intention to
  treat with last observation carried
  forward at 5 years*
Analysed for primary outcome intention to
  treat with conservative imputation†
Analysed for primary outcome per protocol‡
Analysed for time to event
102
103
88
102
Analysed for primary outcome intention to
  treat with last observation carried
  forward at 5 years*
Analysed for primary outcome intention to
  treat with conservative imputation†
Analysed for primary outcome per protocol‡
Analysed for time to event
102
105
78
102
6 month follow-up
1 year follow-up
2 year follow-up
3
1
1
3 year follow-up
4 year follow-up
5 year follow-up
3
7
87
Last observed POP-Q score
available at end of trial
6 month follow-up
1 year follow-up
2 year follow-up
0
4
6
3 year follow-up
4 year follow-up
5 year follow-up
5
6
81
Last observed POP-Q score
available at end of trial
Fig 1 | Flow of women through study. *Intention to treat: two women allocated to vaginal hysterectomy received 
sacrospinous hysteropexy and were analysed in the vaginal hysterectomy group. One woman after vaginal 
hysterectomy had recurrent apical prolapse, but pelvic organ prolapse quantification (POP-Q) score was missing; 
this woman was included in the intention-to-treat last observation carried forward analysis. †Missed data imputed as 
failure. ‡Per protocol analysis: two women did not receive intended treatment. Excluded from per protocol analysis: 
discontinued follow-up at five year (n=22), missing or incomplete POP-Q score (n=18), and major protocol deviations 
(n=9); seven patients met two criteria for exclusion from per protocol analysis
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hysterectomy group (difference 11.5%, 0.8% to 
22.2%). Time-to-event analysis showed success in 70% 
of the women in the sacrospinous hysteropexy group 
and 65% of the women in the vaginal hysterectomy 
group (difference 5.3, −7.9 to 18.5).
Three of 102 women (3%) underwent surgery for 
recurrent prolapse in the sacrospinous hysteropexy 
group compared with seven of 102 women (7%) in 
the vaginal hysterectomy group (difference −3.8%, 
−10.2% to 2.5%). No women (0%) had recurrent 
surgery for pelvic organ prolapse in a non-operated 
compartment in the sacrospinous hysteropexy group 
compared with four of 102 women (4%) in the 
vaginal hysterectomy group (difference −3.8%, 95% 
confidence interval −8.4% to 0.7%). In the time-to-
event analysis three of 102 women (3%) had repeat 
surgery in any compartment in the sacrospinous 
hysteropexy group compared with nine of 102 women 
(9%) in the vaginal hysterectomy group (difference 
−5.9%, 95% confidence interval −12.3% to 0.5%).
During follow-up two women (2%) underwent 
hysterectomy after sacrospinous hysteropexy. Stage 
1 endometrial carcinoma was diagnosed in one 
woman (1%) and laparoscopic hysterectomy was 
performed. The other woman had persistent buttock 
pain immediately after surgery, and the sutures and 
uterus were removed four months after surgery and 
the symptoms resolved. Subsequent surgical treatment 
for stress urinary incontinence was necessary in two 
of 102 women (2%) in the sacrospinous hysteropexy 
group compared with six of 102 women (6%) in the 
vaginal hysterectomy group (difference −3.8%, 95% 
confidence interval −9.7% to 2.0%). Tables 4 and 5 
provide information on functional outcome, quality of 
life, and sexual functioning. Functional outcome and 
quality of life did not differ statistically significantly 
between the groups (table 4). Among the women 
who completed the pelvic organ prolapse/urinary 
incontinence sexual questionnaire before and five years 
after surgery, scores showed statistically significant 
improvement in both groups but no significant 
difference in total scores between both interventions 
(table 5). All serious adverse events potentially related 
to surgical treatment occurred in the first 12 months 
after surgery and have been described previously.6
Discussion
This study provides evidence that treatment of uterine 
prolapse with sacrospinous hysteropexy is effective 
and has lower risk of recurrent bothersome uterine 
prolapse or retreatment of the apical compartment 
compared with vaginal hysterectomy with uterosacral 
ligament suspension. We found no differences in 
overall anatomical failure, functional outcome, quality 
Table 1 | Baseline characteristics of women in the extended trial. Value are numbers (percentages) unless stated 
otherwise
Characteristics Sacrospinous hysteropexy (n=102) Vaginal hysterectomy (n=102)
Median (range) age (years) 63 (45-85) 61 (33-82)
Highest educational level:
 Primary or secondary school 14 (14) 6 (6)
 High school 77 (77) 80 (81)
 Bachelor, master or academic degree 9 (9) 13 (13)
Comorbidity:
 Cardiovascular disease 39 (38) 31 (30)
 Diabetes mellitus 5 (5) 5 (5)
 Respiratory disease 3 (3) 7 (7)
Smoker 13 (15) 9 (10)
Median (range) No of vaginal deliveries 2 (0-7) 3 (0-7)
Median (range) No of caesarean deliveries 0 (0-1) 0 (0-2)
Mean (SD) body mass index 25.9 (3.3) 25.9 (3.5)
POP-Q stage uterine prolapse (point C)*:
 2 66 (65) 65 (64)
 3 28 (28) 28 (28)
 4 8 (8) 9 (9)
POP-Q stage 2-4:
 Anterior prolapse (Ba ≥1) 93 (94) 92 (92)
 Posterior prolapse (Bp ≥1) 29 (29) 32 (32)
Prolapse beyond hymen:
 Apical (POP-Q C >0) 47 (48) 40 (40)
 Anterior (POP-Q Aa or Ba >0) 70 (71) 70 (70)
 Posterior (POP-Q Ap or Bp >0) 11 (11) 11 (11)
Overall POP-Q stage*:
 2 25 (25) 35 (35)
 3 69 (70) 61 (61)
 4 5 (5) 4 (4)
POP-Q=pelvic organ prolapse quantification.
Percentages were calculated using non-missing data. Women were analysed as allocated.
*System involves quantitative measurements of various points of vaginal wall, with hymen as reference point. Degree of prolapse of anterior vaginal 
wall (Aa and Ba), posterior vaginal wall (Ap and Bp), and uterus or vaginal vault (C) measured in centimetres both above or proximal to hymen (negative 
number) or beyond or distal to hymen (positive number), with plane of hymen defined as zero. A represents the descent of a measurement point 3 cm 
proximal to the hymen on the anterior (Aa) and posterior (Ap) vaginal wall. B is the most descended edge on the anterior (Ba) and posterior (Bp) vaginal 
wall. POP-Q stage 2: most distal prolapse is between 1 cm above and 1 cm beyond hymen; stage 3: most distal prolapse is prolapsed >1 cm beyond 
hymen but no further than 2 cm less than total vaginal length; stage 4: total prolapse.
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of life, repeat surgery, and sexual functioning between 
sacrospinous hysteropexy and vaginal hysterectomy 
with uterosacral ligament suspension at five year 
follow-up. However, the proportion of women with 
successful treatment was statistically significantly 
higher after sacrospinous hysteropexy.
Time-to-event analysis showed no differences in 
surgical failure of the apical compartment, overall 
anatomical failure, success, and repeat surgery 
between sacrospinous hysteropexy and vaginal 
hysterectomy with uterosacral ligament suspension.
Strengths and limitations of this study
This randomised trial evaluated efficacy and safety 
of uterus preserving sacrospinous hysteropexy and 
vaginal hysterectomy with uterosacral ligament 
suspension after five year follow-up. A major strength 
of this trial is the sample size and the large group of 
women who completed follow-up. POP-Q scores of 
168 women (81%) were available for analysis. A 
recent systematic review on definitions of success in 
pelvic organ prolapse surgery concluded that most 
studies on such surgery use definitions solely based 
on anatomical criteria.17 We included definitions 
for subjective outcomes and retreatment rates and 
analysed a composite outcome measure in which 
treatment was considered as success when women 
had no bothersome symptoms of prolapse, no surgical 
retreatment or pessary use, and no pelvic organ 
prolapse beyond the hymen as different studies have 
shown that the hymen is an important cut off point for 
symptom development.18-20
The trial also has some limitations. We used the last 
observation carried forward method for missing data, 
with the advantage that it minimises the number of 
dropouts. In our trial, five out of nine (56%) women 
with recurrent pelvic organ prolapse of the apical 
compartment with bothersome symptoms or repeat 
surgery for recurrent apical prolapse withdrew from 
the study before the last study visit. As we evaluated 
outcomes solely at five year follow-up, these recurrences 
would not have been taken into account. However, there 
is a possibility that this method gives a biased estimate 
of the treatment effect and underestimates the variability 
of the estimated result. Prolapse recurrence could have 
occurred after withdrawal. By adding a time-to-event 
analysis using Kaplan-Meier this bias was minimised. 
Another limitation is the use of different types of sutures. 
Table 2 | Outcomes for pelvic organ prolapse at five year follow-up. Values are numbers (percentages) of women unless 
stated otherwise
Outcomes Sacrospinous hysteropexy Vaginal hysterectomy % difference (95% CI)
Surgical failure of apical compartment*:
 ITT analysis with LOCF 1/102 (1) 8/102 (8) −6.7 (−12.8 to −0.7)
 ITT analysis with conservative imputation 16/103 (16) 27/105 (26) −9.8 (−20.9 to 1.2)
 Per protocol analysis 0/88 (0) 4/78 (5) −5.1 (−10.9 to 0.7)
 Time-to-event analysis† 4/102 (4) 9/102 (9) −4.7 (−11.4 to 2.0)
Anatomical failure‡:
 Overall anatomical failure 46/102 (45) 51/102 (50) −4.8 (−18.5 to 8.9)
  Apical compartment 3/102 (3) 7/102 (7) −3.8 (−10.2 to 2.5)
  Anterior compartment 41/102 (40) 36/101 (36) 4.5 (−8.9 to 17.8)
  Posterior compartment 5/102 (5) 18/101 (18) −12.7 (−21.5 to −3.9)
 Time-to-event analysis 73/102 (72) 78/102 (77) −5.0 (−17.1 to 7.1)
Composite outcome success§:
 ITT analysis with LOCF 89/102 (87) 77/102 (76) 11.5 (0.8 to 22.2)
 ITT analysis with conservative imputation 77/103 (75) 65/105 (62) 12.6 (0.0 to 25.2)
 Per protocol analysis 77/88 (88) 62/78 (80) 7.9 (−3.6 to 19.4)
 Time-to-event analysis 71/102 (70) 65/102 (64) 5.3 (−7.9 to 18.5)
Prolapse beyond the hymen¶:
 Apical (POP-Q C >0) 0/102 (0) 4/101 (4) −3.9 (−8.5 to 0.7)
 Anterior (POP-Q Ba >0) 6/102 (6) 8/101 (8) −2.0 (−9.4 to 5.3)
 Posterior (POP-Q Bp >0) 0/102 (0) 3/101 (3) −2.9 (−7.1 to 1.3)
Repeat surgery¶:
 Recurrent prolapse 3/102 (3) 7/102 (7) −3.8 (−10.2 to 2.5)
  Apical compartment 1/102 (1) 4/102 (4) −2.9 (−7.8 to 2.0)
  Anterior compartment 3/102 (3) 4/102 (4) −1.0 (−6.5 to 4.6)
  Posterior compartment 0/102 (0) 2/102 (2) −1.9 (−5.7 to 1.8)
 Different site from primary surgery** 0/102 (0) 4/102 (4) −3.8 (−8.4 to 0.7)
 Time-to-event analysis 3/102 (3) 9/102 (9) −5.9 (−12.3 to 0.5)
Surgery for non-prolapse conditions:
 Surgery for stress urinary incontinence 2/102 (2) 6/102 (6) −3.8 (−9.7 to 2.0)
 Hysterectomy 2/102 (2) - -
 Other 1/102 (1) 1/102 (1) 0 (−3.8 to 3.8)
ITT=intention to treat; LOCF=last observation carried forward; POP-Q=pelvic organ prolapse quantification. Percentages were calculated using non-
missing data. Agresti-Coull method used to calculate 95% confidence intervals.
*Recurrent apical prolapse stage ≥2 with bothersome symptoms or repeat surgery for apical prolapse.
†Time-to-event analysis using Kaplan-Meier to calculate cumulative incidence until five year follow-up.
‡Prolapse POP-Q stage ≥2.
§No prolapse beyond hymen, absence of bothersome bulge symptoms, and no repeat surgery or pessary use.
¶ITT with LOCF.
**Reoperation for pelvic organ prolapse in non-operated compartment.
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Permanent sutures were used in the sacrospinous 
hysteropexy procedure and delayed absorbable sutures 
in uterosacral ligament suspension after vaginal 
hysterectomy as this was the standard procedure in 
the participating hospitals at that time. This difference 
corresponds in general with the way both procedures 
are described in the literature. Currently, evidence is 
unclear about which type of suture material is preferable 
(delayed absorbable versus permanent or a combination 
of the two) and more research is needed on this topic.
In the sacrospinous hysteropexy group the proportion 
of women with anterior compartment anatomical 
failure, defined as a stage 2 pelvic organ prolapse or 
higher of the anterior vaginal wall, was greater after 
12 months (47%) compared with the results at five 
year follow-up (40%). The most plausible explanation 
seems to be interobserver and intraobserver variability. 
The variability of the POP-Q score is, however, regarded 
as low and this scoring system is the only accepted 
one used internationally in scientific research at this 
moment. Overall, a clinically relevant worsening of 
cystoceles over time seems unlikely.
Finally, it was not possible to blind the independent 
doctor or specialist nurse at follow-up to surgical 
intervention, because the cervix is present or absent in 
POP-Q. This is a limitation as it could lead to potential 
bias.
Comparison with other studies
Other randomised studies evaluating uterus preserving 
surgery versus vaginal hysterectomy with apical 
suspension after long term follow-up are not available. 
The risk of recurrent vaginal prolapse in a five year 
retrospective cohort study was 20% after vaginal 
hysterectomy with uterosacral ligament suspension 
based on a composite outcome definition of any 
anatomical prolapse beyond the hymen, or pessary, 
or repeat surgery.20 The risk of recurrent surgery 
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Fig 2 | Survival analysis to estimate the cumulative incidence of surgical failure of the apical compartment, overall anatomical failure, composite 
outcome of success and repeat surgery in any compartment at five year follow-up after sacrospinous hysteropexy and vaginal hysterectomy with 
uterosacral ligament suspension. *Cumulative incidence was number of events (%) that occurred during five year follow-up. Hazard ratios and 
95% confidence intervals were calculated using Cox regression. (Top left) Recurrent apical prolapse stage ≥2 with bothersome symptoms or repeat 
surgery for apical prolapse. (Top right) Pelvic organ prolapse quantification (POP-Q) stage ≥2 in any compartment. (Bottom left) No prolapse beyond 
the hymen, no bothersome bulge symptoms and no repeat surgery or pessary use for recurrent prolapse. (Bottom right) Repeat surgery in any 
compartment
Table 3 | Details for women with surgical failure of apical compartment at 60 months follow-up
Type of surgical failure by procedure Time after primary surgery (follow-up)
Sacrospinous hysteropexy:
 Repeat surgery for apical prolapse 28 months (5 years)
Vaginal hysterectomy:
 Repeat surgery for apical prolapse 27 months (5 years); 11 months (5 years); 10 months (48 months);  
23 months (48 months)
 Recurrent apical prolapse with bothersome symptoms 48 months (5 years); 12 months (24 months); 24 months (24 months)  
12 months (12 months)
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was 10%. Additional analysis of our data using this 
definition confirmed this finding. The risk of recurrent 
prolapse after vaginal hysterectomy with uterosacral 
ligament suspension was 20% (20/102 women). In the 
sacrospinous hysteropexy group this risk was lower 
(9%, 9/102 women, P=0.04). The risk of recurrent 
surgery after vaginal hysterectomy was 9% (9/102 
women) when we included women who had surgery for 
recurrent pelvic organ prolapse or primary surgery for a 
prolapse in a non-treated compartment, or both. After 
sacrospinous hysteropexy this was 3% (3/102 women). 
After five years we found more anatomical recurrences 
of the posterior compartment after vaginal hysterectomy 
with suspension of the uterosacral ligaments, 
although more posterior repairs were performed in 
the vaginal hysterectomy group (50%) compared with 
sacrospinous hysteropexy group (29%). This finding 
is in line with the results after 12 months’ follow-up. 
Generally, it is believed that the more dorsal axis of the 
vagina after sacrospinous hysteropexy might prevent 
recurrent prolapse of the posterior vaginal wall. This is, 
however, speculative because the POP-Q system is not 
an appropriate instrument to show this change in axis, 
and studies with, for example, magnetic resonance 
imaging are lacking. Another possible explanation 
could be the difference in apical suspension between 
the procedures. Because of the low percentage of 
surgical failure of the apical compartment we analysed 
the anatomical features of this compartment. We 
compared the level of the cervix or vaginal vault in 
relation to the hymen (POP-Q point C) at five year 
follow-up. Overall this was significantly lower after 
vaginal hysterectomy with uterosacral ligament 
suspension compared with sacrospinous hysteropexy 
(−5.9 cm v −7.2 cm, P=0.01). Women with posterior 
vaginal wall prolapse stage 2 or higher after both types 
of surgery had statistically significantly lower POP-Q 
point C scores compared with women without posterior 
vaginal wall prolapse. Other anatomical differences 
that could affect the posterior vaginal wall such as 
preoperative and postoperative genital hiatus (distance 
between the external urethral meatus and posterior 
midline hymen) were not found, and perineorrhaphy, 
which can influence the genital hiatus, was not 
routinely performed in both procedures. After vaginal 
hysterectomy, two thirds of the repeat surgeries were 
performed because of recurrent or de novo pelvic organ 
prolapse of the posterior compartment. The number 
of women who underwent repeat surgery was overall 
low, however, and most recurrences were proximal to 
the hymen. The clinical significance of these findings is 
therefore debatable.
Table 4 | Functional outcome and quality of life after sacrospinous hysteropexy and vaginal hysterectomy of women 
included in extended trial at baseline and five year follow-up. Values are medians (interquartile ranges) of domain 
scores unless stated otherwise
Domains
Before surgery 5 years after surgery
Sacrospinous  
hysteropexy
Vaginal  
hysterectomy
Sacrospinous  
hysteropexy
Vaginal  
hysterectomy P value*
Urogenital distress inventory†:
 Overactive bladder 22 (0-44) 22 (0-33) 11 (0-22) 0 (0-19) 0.31
 Urinary incontinence 17 (0-33) 17 (0-33) 0 (0-17) 0 (0-17) 0.33
 Obstructive micturition 0 (0-33) 17 (0-33) 0 (0-17) 0 (0-17) 0.75
 Genital prolapse 50 (33-67) 67 (33-67) 0 (0-0) 0 (0-0) 0.50
 Pain 17 (0-33) 17 (0-33) 0 (0-8) 0 (0-17) 0.72
Defecatory distress inventory†:
 Obstipation 0 (0-17) 0 (0-17) 0 (0-0) 0 (0-0) 0.81
 Obstructive defecation 0 (0-17) 0 (0-15) 0 (0-8) 0 (0-8) 0.93
 Pain 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0.60
 Incontinence 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0.93
 Flatus 33 (0-33) 33 (0-33) 33 (0-33) 33 (0-33) 0.23
Incontinence impact questionnaire‡:
 Mobility 11 (0-33) 11 (0-22) 0 (0-11) 0 (0-11) 0.61
 Physical 0 (0-33) 0 (0-33) 0 (0-0) 0 (0-0) 0.32
 Social 11 (0-22) 0 (0-11) 0 (0-0) 0 (0-0) 0.49
 Embarrassment 0 (0-17) 0 (0-17) 0 (0-0) 0 (0-0) 0.43
 Emotion 0 (0-33) 0 (0-22) 0 (0-11) 0 (0-0) 0.18
Short form-36§:
 Physical functioning 80 (55-90) 80 (70-90) 90 (75-100) 90 (75-100) 0.71
 Social functioning 100 (75-100) 88 (75-100) 88 (75-100) 100 (88-100) 0.18
 Role limitations physical 75 (25-100) 100 (63-100) 100 (94-100) 100 (100-100) 0.99
 Role limitations emotional 100 (100-100) 100 (100-100) 100 (100-100) 100 (100-100) 0.62
 Mental health 84 (72-92) 84 (72-88) 80 (68-88) 84 (76-92) 0.18
 Vitality 70 (50-80) 70 (55-80) 70 (55-80) 75 (61-85) 0.07
 Bodily pain 78 (65-100) 80 (67-100) 90 (67-100) 100 (78-100) 0.39
 General health perception 75 (58-85) 75 (65-85) 75 (60-90) 75 (60-90) 0.72
 Health change 50 (25-50) 50 (50-50) 50 (50-50) 50 (50-50) 0.29
All women were analysed as allocated.
*P value for exploratory purposes: Mann-Whitney U test of sacrospinous hysteropexy versus vaginal hysterectomy at 5 years after surgery.
†0=no symptoms or not bothersome to 100=most bothersome symptoms.
‡0=best quality of life to 100=worst quality of life.
§0=worst quality of life to 100=best quality of life.
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A recent published cohort study from Denmark 
showed that the highest risk for undergoing reoperation 
is within the first year.21 We found that 50% of the 
reoperations were in the first year and 83% in the two 
years after primary surgery. Endometrial carcinoma 
was diagnosed in one woman during follow-up (1%) 
and she underwent laparoscopic hysterectomy. In most 
cases, endometrial carcinoma presents with symptoms 
at a low stage, as was the case here. We believe that 
future risk of malignancy should not be regarded as a 
valid reason for removal of the uterus before adequate 
preoperative investigations have been done.6
Clinical implications and future research
Vaginal hysterectomy is still widely regarded as 
the ideal treatment for uterine prolapse. A recent 
survey among UK practitioners showed that vaginal 
hysterectomy and repair is still the procedure of first 
choice (75%) for uterovaginal prolapse.22 Comparable 
findings were described in a study from Australia and 
New Zealand.23 However, uterus preserving surgery 
is gaining popularity among doctors and women. A 
recent published study on trends in prolapse surgery 
in England found an increase in uterine sparing 
surgery.24 This trend is in line with a change in women’s 
attitudes and preference for uterus preservation.25-27 
On the other hand, in response to our previous report 
on the SAVE U study, some argued that the uterus is 
an atrophic, non-functional organ and that uterus 
preservation on cultural or ideological grounds should 
be rejected.28 In our opinion this reflects a serious 
disregard of women’s attitudes and feelings. Although 
vaginal hysterectomy is still the preferred treatment we 
believe that the results of our study together with the 
increasing knowledge of women’s preference will lead 
to better informed decision making by women and their 
gynaecologists, in which sacrospinous hysteropexy is 
a valid option.
A recent review discussed several variations in 
technique of the sacrospinous hysteropexy.29 In 
our study the sutures were placed under direct 
vision through the sacrospinous ligament. Newer 
disposable ligature carriers are used to facilitate 
blind suture application using minimal dissection. A 
study comparing open sacrospinous colpopexy with 
colpopexy using the Capio suture capturing device 
(Boston Scientific, MA) in 86 women after hysterectomy 
reported no difference in objective and subjective 
success after three years.30 However, no randomised 
trials are available that compare this device or other 
suture capturing devices with open sacrospinous 
hysteropexy, as performed in our study. Although 
suturing devices might be potentially beneficial for 
blood loss and duration of operation, they should 
only be implemented after adequate clinical research. 
The SAVE U study group consisted of women with 
POP-Q stage 2 and higher. The effect of sacrospinous 
hysteropexy in a lower stage pelvic organ prolapse 
still needs to be established, as well as the effect on a 
predominant cystocele or rectocele.
More randomised trials comparing other uterus 
preserving surgical techniques are needed to compare 
efficacy and safety of the different procedures. In the 
Netherlands two large randomised controlled studies 
comparing modified Manchester procedure with 
sacrospinous hysteropexy (trialregister.nl NTR 6978) 
and laparoscopic hysteropexy with sacrospinous 
hysteropexy (trialregister.nl NTR 4029) have started.31
Conclusions
We conclude that, based on results five years after 
surgery, sacrospinous hysteropexy is an effective 
and safe alternative to vaginal hysterectomy with 
suspension of the uterosacral ligaments for treatment 
of uterine prolapse. Surgical failure, defined as 
recurrent apical prolapse with bothersome symptoms 
or repeat surgery for recurrent apical prolapse, was 
less often found after uterus preservation, and the 
proportion of women with successful treatment was 
higher at five year follow-up. Overall anatomical 
failure, functional outcome, repeat surgery, and 
sexual functioning did not differ between the two 
procedures. Furthermore, time-to-event (survival) 
analysis at five years showed no differences in surgical 
failure of the apical compartment, overall anatomical 
failure, surgical retreatment, and composite outcome 
of success between sacrospinous hysteropexy 
and vaginal hysterectomy with suspension of the 
uterosacral ligaments.
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